Drug Profile
Research programme: peptide-drug conjugates - Phi Pharma
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Phi Pharma
- Developer Drugs for Neglected Diseases Initiative Foundation; HES-SO Valais-Wallis; Phi Pharma
- Class Drug conjugates; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute myeloid leukaemia; Leishmaniasis
Highest Development Phases
- No development reported Acute myeloid leukaemia; Leishmaniasis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Switzerland
- 28 Nov 2020 No recent reports of development identified for research development in Leishmaniasis in Switzerland
- 26 Apr 2017 Research programme: peptide-drug conjugates - Phi Pharma is available for licensing as of 26 Apr 2017. http://www.phi-pharma.com (Phi Pharma website, April 2017)